



HAL
open science

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?

Chloe Prod'Homme, Licia Touzet, Magali Pierrat, Luc Chevalier, Helene Lesaffre, Celine Berthon, Valérie Coiteux, Sarah Barbieux, David Beauvais, Loïc Bauschert, et al.

► To cite this version:

Chloe Prod'Homme, Licia Touzet, Magali Pierrat, Luc Chevalier, Helene Lesaffre, et al.. Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?. Blood Advances, 2021, Blood Advances, 5, pp.2123-2127. 10.1182/bloodadvances.2021004369 . hal-04485942

HAL Id: hal-04485942

<https://hal.univ-lille.fr/hal-04485942>

Submitted on 1 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

TO THE EDITOR:

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?

Chloé Prod'homme,¹ Licia Touzet,¹ Magali Pierrat,¹ Luc Chevalier,¹ Helene Lesaffre,¹ Celine Berthon,² Valerie Coiteux,² Sarah Barbieux,² David Beauvais,² Loïc Bauschert,¹ Marie De Charette,² Laure Goursaud,² Salomon Manier,² and Thierry Facon²

¹Palliative Care Unit, and ²Hematology Unit, University of Lille, Centre National de la Recherche Scientifique, CHU Lille, Lille, France

Patients with hematological malignancies (HMs) have less access to palliative care (PC) than other patients with cancer and benefit from it later on in the course of their disease, although symptom burden is just as heavy.¹⁻⁴ We created a specialized outpatient PC consultation in the hematology department to improve the quality of patient management and enhance cooperation with hematologists. We found that although patient characteristics and survival were extremely variable, they all had in common a need for symptom management and care coordination. As a result of the consultation, hematology teams called upon a specialized PC multidisciplinary team more often to meet patients hospitalized within their departments, and more patients with HMs were hospitalized in PC units.

Recent evidence has demonstrated the feasibility, acceptability, and efficacy of integrating PC to improve the quality of life and care of patients with HMs and their caregivers.⁵⁻⁷ Despite clear recommendations to integrate PC in oncology, and in particular, hematocology, the question of what, when, and how to integrate it has yet to be answered.⁸ The constructs of integration plans are needed, adapted to national, regional, and local organizations of oncology and palliative care, as well as to the culture of the organization.

This new real-world intervention consisted of opening a specialized PC consultation one half day per week in 2018 by a doctor trained in both hematology and PC in a University Hospital that has the status of Regional Reference Center in Hematology in Northern France. Patients were referred by hematologists via direct contact between physicians, who discussed the indication before informing patients of the referral. PC consultation was directed to patients with aggressive and potentially mortal HMs and their families. The overall objective was to improve patient and family quality of life by improving symptom burden, in particular, in complex situations.

Information on the goals, criteria, and practical modalities of patient referral to PC consultation was provided to the hematologists who referred the patient. The same team also received training sessions on the benefits of early PC for patients with a malignancy, and particularly for patients with HMs. PC consultation was not advertised to general practitioners, patients, or families, as hematologists feared that the term "palliative" would trigger negative representations.

Twenty-three patients were followed up over a 1-year period (Table 1). Average age was 75 years (range: 40 to 93), and 12 patients were women (Table 1). Disease distribution was comparable to disease distribution in the hematology department: 13% myeloma, 56.5% lymphoma, 30.5% myeloid diseases. Three patients had been allogeneic-hematopoietic-stem cell transplanted, and 1 patient had been treated with chimeric antigen receptor T cells.

During this consultation, treatments for nociceptive pain relief were introduced for 13 patients (56.5%), and treatment of neuropathic pain was introduced in 1 patient. Anxiolytics were introduced or modified for 6 patients, and psychological counseling was begun for 4 patients. Of the patients, 52% described psychological symptoms that were deemed "difficult." Laxatives, treatments for oral mycosis, and digestive discomfort were prescribed. Infections were also managed and treated. A total of 87% of patients presented uncomfortable symptoms that required treatment (Table 2). This confirms the need for global palliative assessment and management of patients with advanced HMs.² An advanced care

Table 1. General characteristics of patients

Patients	Age, y	Sex	Disease	HSCt or CAR T cell	Previous contact with PC team	Referred by	Hematology follow-up	Survival after first consultation, d	Oncologic treatment	Number of consultations	Referrals to emergency department	Number of hospitalizations and length of stay, d	Time between consultation and hospitalization, d	Blood transfusions	Place of death
P1	78	F	AML	No	No	Hematologist	Yes	86	No	1	1	2 (7 + 13)	43	1	PC department
P2	73	F	Diffuse B lymphoma	No	No	Hematologist	No	112	Yes, radiotherapy	2	1	1 (5)	107	0	Medical department
P3	80	M	Myeloma	No	No	Hematologist	Yes	8	No	1	1	1 (7)	1	0	Medical department
P4	84	F	AML	No	No	Hematologist	No	33	No	1	0	0	0	0	Home
P5	82	M	Diffuse B lymphoma	No	Yes	PC department	No	26	Yes, radiotherapy	1	0	0	0	0	Home
P6	62	M	Myeloma	Yes	No	Hematologist	No	59	No	2	0	0	0	3	Home
P7	79	F	AML	No	No	Hematologist	Yes	97	No	2	0	0	0	0	Home
P8	40	F	Hodgkin lymphoma	Yes	No	Hematologist	Yes	70	Yes, target therapy	3	1	1 (1)	69	0	PC department
P9	83	M	MDS	No	Yes	Hematologist	Yes	63	No	3	1	2 (2 + 5)	2	3	PC department
P10	88	M	Mantle cell lymphoma	No	No	Hematologist	No	335	Yes, target therapy	5	0	0	0	0	0
P11	88	M	Hodgkin lymphoma	No	No	Hematologist	No	24	No	1	0	1 (23)	1	0	PC department
P12	88	F	AML	No	No	Hematologist	No	9	No	1	0	1 (9)	0	0	PC department
P13	81	F	Myeloma	No	No	Hematologist	Yes	101	Yes, IV chemotherapy	2	1	1 (2)	99	1	Emergency department
P14	60	M	T lymphoma	No	No	Hematologist	Yes	186	Yes, oral chemotherapy	4	1	1 (25)	166	2	0
P15	80	M	Mantle cell lymphoma	No	No	Hematologist	No	32	Yes, oral chemotherapy	1	0	1 (18)	13	0	PC department
P16	82	F	Hodgkin lymphoma	No	No	Hematologist	Yes	159	Yes, oral chemotherapy	1	0	0	0	0	0
P17	85	M	T lymphoma	No	No	Hematologist	Yes	123	No	1	0	0	0	0	0
P18	92	M	Burkitt lymphoma	No	No	Hematologist	No	109	Yes, targeted therapy	1	0	0	0	0	Home
P19	63	F	Diffuse B lymphoma	Yes	No	Hematologist	No	122	No	3	0	1 (12)	98	2	Home
P20	52	F	Diffuse B lymphoma	No	No	Hematologist	Yes	109	Yes, targeted therapy	1	0	0	0	0	0
P21	85	F	AML	No	No	Hematologist	No	14	Yes, oral chemotherapy	1	1	1 (10)	4	0	Medical department
P22	41	M	ALL	Yes	No	Hematologist	No	28	No	2	0	1 (1)	28	2	PC department
P23	93	F	Diffuse B lymphoma	No	No	Hematologist	Yes	18	Yes, oral chemotherapy	1	0	0	0	0	0

ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; F, female; HSCT, allogeneic stem cell transplantation; M, male; MDS, myelodysplastic syndrome.

Table 2. PC need

Patient	Pain	Anxiety	Other symptoms	Referrals	Home care plan	Prescription modification	Limitation of blood transfusions	Advance care planning	Multidisciplinary management
P1	Yes	Yes	Constipation	No	Yes	Yes	No	Yes	Yes/home care support team
P2	Yes	Yes	Constipation, hypercalcemia	Yes	Yes	Yes	No	Yes	Yes/home care support team
P3	Yes	Yes		No	No	Yes	No	Yes	Yes/multidisciplinary PC team
P4	Yes	No	Nausea, oral mycosis	No	Yes	No	Yes	Yes	Yes/home care support team
P5	Yes	No	Constipation, bleeding symptoms	Yes	No	Yes	No	Yes	Yes/PC department
P6	No	Yes	Asthenia	No	Yes	Yes	Yes	Yes	Yes/multidisciplinary PC team
P7	No	Yes		No	Yes	Yes	Yes	Yes	No
P8	Yes	Yes	Constipation, arthralgia, myalgia fewer	Yes	Yes	No	No	Yes	Yes/home care support team
P9	No	Yes	Constipation, dry mouth	No	Yes	Yes	Yes	Yes	Yes/multidisciplinary PC team
P10	No	Yes	Diarrhea, dyspnea	Yes	Yes	No	No	Yes	Yes/home care support team
P11	No	Yes	Diarrhea, dyspnea	No	No	No	No	No	Yes/PC department
P12	Yes	No	Dyspnea	No	No	No	Yes	No	Yes/PC department
P13	No	No		No	No	Yes	No	Yes	No
P14	Yes	Yes	Oral mycosis	No	Yes	Yes	No	Yes	Yes/home care support team
P15	Yes	Yes	Nausea, constipation	No	Yes	No	No	Yes	Yes/home care support team and PC department
P16	Yes	No	Constipation	Yes	Yes	No	No	Yes	Yes/home care support team
P17	No	No		No	No	Yes	No	Yes	Yes/home care support team
P18	No	No		No	No	Yes	No	Yes	Yes/Home hospitalization
P19	Yes	No	Clostridium infection, dysphagia	Yes	No	Yes	No	Yes	Yes/PC department and home hospitalization
P20	Yes	No		No	No	No	No	No	No
P21	No	No	Asthenia, malaise	No	Yes	No	Yes	Yes	No
P22	Yes	Yes	Bleeding, cystitis	No	Yes	Yes	Yes	Yes	Yes/PC department
P23	No	No	Asthenia, oral mycosis	No	Yes	Yes	No	Yes	Yes/home care support team

plan was discussed and written with 19 patients. It was systematically sent by mail to all other health care professionals involved with the patient. In 14 cases, the home care plan was enhanced with the intervention of a nurse, a nurse's aide, or a live-in caregiver (Table 2). Treatments deemed futile or inappropriate were discussed with the general practitioner either upon initiation of PC or later in the course of evolution for 14 patients. Blood transfusions were limited or terminated in 7 patients, at their request, after a discussion with hematologists and their general practitioner (Table 2). Discussions on the matter between PC physician and hematologists occurred twice.

Between the first consultation and patient's death, only 8 patients were addressed to the emergency department, 7 of which led to hospitalization ending with death. Eight patients were hospitalized without passing through the emergency department. Mean time between the first PC consultation and hospitalization was 52 days (range, 1 to 107) (Table 1). Among the 17 patients who died during the 12-month period, one was lost to follow-up, 6 died at home as per their advanced care plan, 11 died at hospital, 7 died in a PC department, and 1 died in an emergency department short-stay unit (Table 1). As per the criteria of Earle et al of aggressive care in end-of-life cancer treatment, no patient received IV chemotherapy <14 days before death, nor was any patient hospitalized in intensive care, sent to the emergency department more than once, or hospitalized within the last month of life.^{3,9,10}

PC-hematology collaboration was enhanced: between 2014 and 2017; inpatients with HMs represented 4.5% of patients followed by the inpatient multidisciplinary PC team, whereas after setting up PC consultation, their numbers increased to 5.7%. Moreover, 70% (10.5 vs 18 patients) (Student *t* test; *P* < .05) more hematology patients were hospitalized in a PC unit in 2018 to 2019, after PC consultation initiation. Unformal training through discussions and bedside care was also achieved by means of this collaboration.

One limiting factor was the referral of patients by hematologists alone. Although hematologists are the most legitimate to introduce PC into the privileged patient-doctor relationship, and although they acknowledge that access to specialized PC care improves quality of end of life, barriers to addressing patients to PC specialists remain.¹¹⁻¹⁴ This could explain the small number of referrals over a 12-month period, despite the fact that PC consultations were conducted by a hematologist better able to overcome cultural barriers to PC integration and trust issues that have been discussed in multiple studies as potential barriers to PC integration.⁴ A Spanish study has previously demonstrated the benefits of a specialized PC consultation with a physician trained in both PC and hematology among patients with multiple myeloma. In this study, patients were recruited via the PC team: a PC nurse presented the benefits of consultation over the phone to all multiple myeloma patients that were progressing.¹⁵ Another limitation is that there may be few hematologists trained in PC, so that this model may not easily be reproducible elsewhere. In any case, facilitating patient access to PC consultations and increasing collaboration probably require PC training to be reiterated regularly among hematologists. Informing patients, families, and general practitioners of the possibility also seems crucial on the path to providing patients with more autonomy in the management their severe disease and end of life.

Another question raised by this PC consultation is that of the allotment of responsibilities between hematologists and PC doctor: when the patient is hospitalized in hematology, the specialized PC team provides expertise to hematologists but does not prescribe, but in the outpatient setting, the PC doctor can prescribe. Although prescriptions for symptom management were not systematically discussed with the referring hematologist, he was called upon every time there was talk of discontinuing oncological treatments. This is an area that has worried hematologists historically: there is a fear that PC specialists might "talk their patients out of curative/helpful treatments."^{3,16-18}

The quality of PC implementation for HM patients in the outpatient setting was improved by setting up a specialized PC consultation within the Hematology Department. Nevertheless, collaboration is still under construction to overcome cultural barriers and allow peaceful trust between the 2 teams.

Contribution: C.P. performed the research; C.P. and M.P. analyzed the data; C.P. and L.T. wrote the paper; C.P. and T.F. designed the research; C.P., L.T., M.P., L.C., L.B., and H.L. are a part of the interdisciplinary palliative care team that worked with hospitalized hematology patients; and C.B., V.C., S.B., D.B., M.D.C., L.G., and S.M. addressed patients to palliative care consultation.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: C.P., 0000-0002-1990-5219; C.B., 0000-0002-3474-2577; L.B., 0000-0002-1451-8762.

Correspondence: Chloé Prod'homme, University of Lille, CNRS, CHU Lille, Palliative Care Unit, F-59000 Lille, France; e-mail: chloe_prodhomme@hotmail.com.

References

1. Howell DA, Wang H-I, Roman E, et al. Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myeloma. *BMJ Support Palliat Care*. 2015;5(5):496-502.
2. Manitta V, Zordan R, Cole-Sinclair M, Nandurkar H, Philip J. The symptom burden of patients with hematological malignancy: a cross-sectional observational study. *J Pain Symptom Manage*. 2011; 42(3):432-442.
3. LeBlanc TW, O'Donnell JD, Crowley-Matoka M, et al. Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. *J Oncol Pract*. 2015;11(2):e230-e238.
4. El-Jawahri A, Nelson AM, Gray TF, Lee SJ, LeBlanc TW. Palliative and end-of-life care for patients with hematologic malignancies. *J Clin Oncol*. 2020;38(9):944-953.
5. El-Jawahri A, Traeger L, Greer JA, et al. Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial. *J Clin Oncol*. 2017;35(32):3714-3721.
6. El-Jawahri A, LeBlanc T, VanDusen H, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. *JAMA*. 2016;316(20): 2094-2103.
7. El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial. *JAMA Oncol*. 2021;7(2):238-245.

8. Kaasa S, Loge JH, Aapro M, et al. Integration of oncology and palliative care: a Lancet Oncology Commission. *Lancet Oncol*. 2018;19(11): e588-e653.
9. Earle CC, Neville BA, Landrum MB, et al. Evaluating claims-based indicators of the intensity of end-of-life cancer care. *Int J Qual Health Care*. 2005;17(6):505-509.
10. Odejide OO, Salas Coronado DY, Watts CD, Wright AA, Abel GA. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. *J Oncol Pract*. 2014;10(6): e396-e403.
11. Odejide OO, Cronin AM, Condrón NB, et al. Barriers to quality end-of-life care for patients with blood cancers. *J Clin Oncol*. 2016; 34(26):3126-3132.
12. Tricou C, Munier S, Phan-Hoang N, Albarracín D, Perceau-Chambard É, Filbet M.. Haematologists and palliative care: a multicentric qualitative study [published online ahead of print 26 February 2019]. *BMJ Support Palliat Care*. doi:10.1136/bmjspcare-2018-001714.
13. Prod'homme C, Jacquemin D, Touzet L, Aubry R, Daneault S, Knoops L. Barriers to end-of-life discussions among hematologists: A qualitative study. *Palliat Med*. 2018;32(5):1021-1029.
14. Odejide OO, Cronin AM, Earle CC, Tulskey JA, Abel GA. Why are patients with blood cancers more likely to die without hospice? *Cancer*. 2017;123(17):3377-3384.
15. Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, et al. Is early palliative care feasible in patients with multiple myeloma? *J Pain Symptom Manage*. 2017;54(5):692-700.
16. Wright B, Forbes K. Haematologists' perceptions of palliative care and specialist palliative care referral: a qualitative study. *BMJ Support Palliat Care*. 2017;7(1):39-45.
17. McGrath P. Haematology and palliative medicine: moving forward. *Ann Palliat Med*. 2014;3(1):16-18.
18. LeBlanc TW, Roeland EJ, El-Jawahri A. Early palliative care for patients with hematologic malignancies: is it really so difficult to achieve? *Curr Hematol Malig Rep*. 2017;12(4):300-308.